Table 2

Baseline details of LN patients

Patient ID	Sex	Age	Ethnicity	Biopsy result	Urine PCR (mg/mmol)	Serum albumin (g/L)	Treatment at time of biopsy* (mg)
LN1	F	49	Asian	III	58	38	P20, H400
LN2	F	34	White	IV,V	457	30	P20, MP
LN3	F	20	Black	V	123	28	P30, H400
LN4	F	31	White	IV	533	21	P10, H400, M1500
LN5	F	30	White	V	569	23	P10, H400
LN6	F	35	Black	III	202	30	P5, C
LN7	F	29	Asian	III	96	20	P15, A100
LN8	F	33	Asian	III/V	208	36	P12.5, H200
LN9	F	27	Asian	III	34	28	P60, C
LN10	F	18	Asian	IV	66	44	P10, M2000
LN11	M	19	Asian	IV	1017	17	P20, M1000, C
LN12	F	43	White	II	312	34	H400
LN13	F	48	White	II	127	33	H400, MP
LN14	F	34	White	V	366	34	P20, A100
LN15	F	56	White	III/V	88	43	P5, A100
LN16	F	28	Black	IV/V	297	37	P20
LN17	F	21	Asian	IV	65	43	P15, A 150

*In a number of cases, the treatment was changed as a result of the biopsy (eg, the addition of immunosuppressant drugs to high-dose corticosteroids) but those drugs are not included in the table as they would have no effect on samples taken before the drug was started, that is, at the time of the biopsy.
(M)P, (methyl)prednisolone; A, azathioprine; C, cyclophosphamide; H, hydroxychloroquine; LN, lupus nephritis; M, mycophenolate mofetil; PCR, protein creatinine ratio.